Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha

Number of patents in Portfolio can not be more than 2000

United States of America

PATENT NO 12258393
APP PUB NO 20210363234A1
SERIAL NO

17325743

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

A method of treating inflammatory bowel disorders, such as ulcerative colitis, comprises administering an IL-23 inhibitor, such as an anti-IL-23p19 antibody (e.g., guselkumab) and a TNF-α inhibitor, such as an anti-TNF-α antibody (e.g., golimumab).

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
JANSSEN BIOTECH INC800/850 RIDGEVIEW DRIVE HORSHAM PA 19044

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Germinaro, Matthew Philadelphia, US 7 3
O'Brien, Christopher Lafayette Hill, US 33 170
Perrigoue, Jacqueline Oreland, US 4 6
Vetter, Marion Spring House, US 2 4

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Sep 25, 2028
7.5 Year Payment $3600.00 $1800.00 $900.00 Sep 25, 2032
11.5 Year Payment $7400.00 $3700.00 $1850.00 Sep 25, 2036
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00